Edema Associated With Heart Failure — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for edema associated with heart failure. 2 active patents protecting 1 drugs from 0+ originators. First major cliff: 2033. Daily refresh.

1
Approved drugs
2
Active US patents
42/100
Avg vulnerability
—
Annual revenue covered

Originators in Edema Associated With Heart Failure

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating edema associated with heart failure. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
TORSEMIDE — 2 42 — 2033-10-06

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10154963 TORSEMIDE formulation 42 2033-10-06
10154963 TORSEMIDE formulation 42 2033-10-06

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10154963 TORSEMIDE formulation 42 2033-10-06
10154963 TORSEMIDE formulation 42 2033-10-06

Related